A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.
about
Haptoglobin binds the antiatherogenic protein apolipoprotein E - impairment of apolipoprotein E stimulation of both lecithin:cholesterol acyltransferase activity and cholesterol uptake by hepatocytesPotent D-peptide inhibitors of HIV-1 entryDesign of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceDevelopment of a small D-enantiomeric Alzheimer's amyloid-β binding peptide ligand for future in vivo imaging applicationsStyryl-based and tricyclic compounds as potential anti-prion agentsPreventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors.Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.Mirror image phage display--a method to generate D-peptide ligands for use in diagnostic or therapeutical applications.Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.Peptides for therapy and diagnosis of Alzheimer's disease.Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimagingApolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms.Effects of apoE deficiency and occlusal disharmony on amyloid-beta production and spatial memory in ratsOverexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid depositionBlocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice.Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhagesApolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels.Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample.Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic miceImmunological and anti-chaperone therapeutic approaches for Alzheimer disease.Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease.Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.Arginine-, D-arginine-vasopressin, and their inverso analogues in micellar and liposomic models of cell membrane: CD, NMR, and molecular dynamics studies.Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samplesDisease modifying therapy for AD?100 years and counting: prospects for defeating Alzheimer's diseaseUSE OF FUSED CIRCULATIONS TO INVESTIGATE THE ROLE OF APOLIPOPROTEIN E AS AMYLOID CATALYST AND PERIPHERAL SINK IN ALZHEIMER'S DISEASE.Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degenerationTherapeutic approaches for prion and Alzheimer's diseases.Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease.Diseases of protein aggregation and the hunt for potential pharmacological agents.Novel strategies for Alzheimer's disease treatment.Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid.Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivoBACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.
P2860
Q24316403-EB9E9291-A6F9-41D3-89DB-5459E4A8A330Q24675493-F5F67A38-6193-48BA-8660-10CC59B239A8Q27664086-AC5C3685-31DF-4024-B75E-A809DC7B1943Q28728851-E95E52C8-B0E5-42E5-B22F-8F21FF7485B5Q28740431-3BD1A1B5-5ABE-4218-B0F5-F2F565903700Q30855109-B001A650-3EA1-40B5-9D1C-7AC8D2312671Q33248701-A3795761-0493-4D94-8E2B-724E087EAB63Q33482171-7420C801-11A5-4076-B553-533D0CBBB272Q33694502-ED3B4800-032F-46F9-A0A9-3520A05FF0B0Q33725397-0A6D65AF-2ED2-4224-BD1E-25A071ABDAB2Q33742312-EF06F8A7-BB68-4CA6-A346-103CA7290B96Q34124260-7E657BE0-7C79-4326-AB56-341FD08AB402Q34240270-BF548B47-A280-4AAA-A986-7829FC847AE4Q34584517-E37B16B7-253E-4F8A-BF1F-5985D040114AQ34611770-FBCA8C5D-D222-4152-89B0-AA1BDEA223F4Q34628212-650F6F74-E645-45CE-93BA-8D8D144E19DDQ34997429-63B07893-C874-48C4-972C-BD376347D968Q35087794-90BD630A-E63E-4871-A38E-C06F789FC0CCQ35095392-D2613150-28BB-40BA-A535-953D852DD0C2Q35157420-B9E15EEF-B4F0-42DE-BE60-4BA99353BB5BQ35606537-713A42AA-4152-4181-82EB-F99C33D42D3EQ35694025-099A56CE-CC03-48BA-B005-7BAC9A347648Q35717717-68D88B77-A873-42AC-80FA-4723F80E5F0DQ35750144-DF9D642C-6208-4D97-8BD2-0F162CFB67B0Q36075474-FF34E350-FD04-4BAE-ADC7-04620FD44E7CQ36139139-F6B1177D-5DBB-4C1D-A55B-D457F186D0E0Q36231741-ED4ABFE7-CF2A-4AD8-8A17-50D612BA2E5EQ36236101-985F023B-2232-418D-92AF-981184EA3F47Q36635968-97C2EE8A-9AD2-4D94-B801-B7F45246265CQ36640414-FFD202BA-8A76-404A-8607-D7B24858C0BFQ36643419-FD20A921-2BCB-4B57-BC21-1C786BBFFDABQ36792697-5F3FE1EB-B7F2-48FA-85A7-8B54A2BD5EA0Q36817618-DDAD9CD9-8951-43BA-9F37-631A3E0366C6Q36872884-FD5FF8D9-00B9-48F1-971F-4DA5D54A2CDCQ36961152-C7D9BEFD-EDC9-4D69-BE46-099439375E8FQ37011874-4AA767C7-B570-42B4-B439-380E079D0561Q37012066-97044CED-D6C3-4640-A64D-D40B637516DDQ37155515-3C7BF9E3-18CA-4D02-B078-97F9B6CF1D54Q37267798-B7E155B3-24FB-4152-B9CB-F44D3BB7711AQ37598601-BF4F1A02-88CB-4D5C-BEFF-6DA81366D610
P2860
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A synthetic peptide blocking t ...... id plaques in transgenic mice.
@ast
A synthetic peptide blocking t ...... id plaques in transgenic mice.
@en
type
label
A synthetic peptide blocking t ...... id plaques in transgenic mice.
@ast
A synthetic peptide blocking t ...... id plaques in transgenic mice.
@en
prefLabel
A synthetic peptide blocking t ...... id plaques in transgenic mice.
@ast
A synthetic peptide blocking t ...... id plaques in transgenic mice.
@en
P2093
P2860
P50
P1476
A synthetic peptide blocking t ...... oid plaques in transgenic mice
@en
P2093
David M Holtzman
Henrieta Scholtzova
James A Ripellino
Joanna Pankiewicz
John D Fryer
Paul M Mathews
Stephen D Schmidt
Yongsheng Li
P2860
P304
P356
10.1016/S0002-9440(10)63355-X
P407
P577
2004-09-01T00:00:00Z